同步财经IKT
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
时间：2025-02-18 21:00:00 市场： 美股 综合
Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability
时间：2025-01-30 05:58:37 市场： 美股 综合
Inhibikase Therapeutics Inc - Terminates Atm Agreement With With H.c. Wainwright & Co Llc Effective December 11, 2024
时间：2024-12-06 05:58:49 市场： 美股 综合
SP Ikt Holdings Llc Reports 8.69% Passive Stake in Inhibikase Therapeutics Inc as of October 21 - SEC Filing
时间：2024-10-29 05:30:02 市场： 美股 综合
Sands Capital Life Sciences Pulse Fund Ii, L.p. Reports 16.3% Passive Stake in Inhibikase Therapeutics, Inc as of Oct 21 - SEC Filing
时间：2024-10-26 05:52:58 市场： 美股 综合
Perceptive Advisors Llc Reports 9.99% Passive Stake in Inhibikase Therapeutics Inc as of Oct 21- SEC Filing
时间：2024-10-23 04:18:11 市场： 美股 综合
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of Ikt-001Pro Into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
时间：2024-10-21 21:05:25 市场： 美股 综合
Commodore Capital Lp Reports 9.99% Passive Stake in Inhibikase Therapeutics Inc as of Oct 9, 2024- SEC Filing
时间：2024-10-18 04:11:31 市场： 美股 综合
Inhibikase Therapeutics Inc: on October 9 Co Entered Into Securities Purchase Agreement in Connection With a Private Placement
时间：2024-10-11 05:34:27 市场： 美股 综合
Point72 Asset Management Reports 8.4%Passive Stake in Inhibikase Therapeutics as of Oct 9- SEC Filing
时间：2024-10-11 04:19:01 市场： 美股 综合